Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,676.55
(
-0.59%
)
US TECH 100
24,040.40
(
-0.38%
)
Dow Jones
46,549.03
(
-0.95%
)
Brent Oil
105.63
(
4.94%
)
Bitcoin
71,199.90
(
-3.71%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: palindromy post# 48882

Saturday, 06/23/2007 5:09:36 PM

Saturday, June 23, 2007 5:09:36 PM

Post# of 257253
>For most biologics, the manufacturer would have requested and got a patent term extension under 35 USC 156. The practical limit seems to be 14 yrs from date of approval. This would be an easy way of looking at upcoming expiry I guess.<

That would work if there were no ancillary patents in play. But it’s the ancillary patents that make life so complicated!

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now